Advertisement

Topics

AVEO Oncology Announces Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma Reaches Enrollment Target

07:00 EDT 20 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
– Pre-planned futility analysis of the trial expected midyear 2017; topline data expected in the first quarter of 2018 – AVEO Oncology (NASDAQ: AVEO) today announced that the Company’s pivotal TIVO-3 trial, a...

Other Sources for this Article

AVEO:
Argot Partners
David Pitts, 212-600-1902
aveo@argotpartners.com

NEXT ARTICLE

More From BioPortfolio on "AVEO Oncology Announces Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma Reaches Enrollment Target"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Renal Cell Carcinoma
Renal cell cancer (renal adenocarcinoma or hypernephroma) is the most common type of kidney cancer in adults. More than 8 in every 10 (80%) kidney cancers diagnosed in the UK are this type.  In renal cell cancer the cancerous cells start in the lini...